Glioma is a kind of refractory primary intracranial malignant tumor. Overexpression of hepatocyte growth factor（ HGF） and amplification or mutation of MET gene will both lead to abnormal activation of MET pathway. Hyperactivation of MET pathway， the canonical oncogenic pathway， promotes the proliferation， migration， angiogenesis and other tumor microenvironment factors of glioma cells， and eventually lead to malignant progression or therapeutic resistance. Based on the research and understanding of MET gene alterations and the important role of MET pathway in the development and progression of glioma， anticancer drugs targeting MET pathway are regarded as one of the most promising development directions of glioma therapy. Currently， a variety of drugs targeting MET had been successfully developed and several clinical trials had been proposed for application of these drugs in glioma treatment. This paper reviews the characteristics and role of MET alterations in glioma， as well as clinical trials of drugs targeting MET pathway.